September 23, 2008 - The number of newly-diagnosed cancer patients age 65 and older who are enrolled in Medicare’s Health Maintenance Organization (HMO) plans has increased by 6 percent within the past four years, and is shown to limit patients’ participation in clinical trials because they believe they cannot afford the plan’s out-of-pocket expense, according to a first-of-its-kind study presented at ASTRO 2008.

While nearly two-thirds of cancer patients are age 65 and older, less than one-third of patients in this age group are enrolled in clinical trials. Health insurance coverage costs have been cited by elderly patients as reasons why they don’t enroll in clinical trials. This disparity suggests it may be related to Medicare HMO payment policy, which requires additional personal expense for clinical trial participation and may vary depending on the HMO plan. Medicare reimbursement policies differ between fee-for-service (FFS) and HMO plans.

“Clinical trials are the cornerstone in finding better, more effective cancer treatments,” said Chyongchiou Lin, Ph.D., lead author of the study and an associate professor of health economics at the University of Pittsburgh Cancer Institute’s Department of Radiation Oncology in Pittsburgh. “The National Cancer Institute has made clinical trial participation a top, national priority, yet current Medicare reimbursement policies show it might be a barrier for participation by a large number of patients with Medicare HMO coverage and discourages cutting-edge treatment options for a very vulnerable population. The current policy should be re-examined to be consistent with NCI initiatives.”

The study shows that the overall proportion of newly-diagnosed cancer patients who had consultations and were insured by Medicare HMOs increased from 21 percent in 2003 to 27 percent in 2007 in five hospitals participating in the UPMC McKeesport Radiation Oncology Community Outreach Program (ROCOG), a consortium of hospitals in Western Pennsylvania, funded by the NCI’s Radiation Research Program and the Cancer Disparities Research Partnership, that focuses on improving access and outcomes for underserved populations with cancer. The research team in the lead community hospital participating in the program found in 2007 that patients eligible for innovative clinical trials opted out of enrolling in a “Medicare Qualifying” clinical trial due to the financial burden of participating.

For more information: www.astro.org

Source: American Society For Therapeutic Radiology and Oncology


Related Content

News | Stereotactic Body Radiation Therapy (SBRT)

October 1, 2023 — Older adults diagnosed with kidney tumors that are not suitable for surgery may benefit from targeted ...

Time October 01, 2023
arrow
News | Radiation Oncology

May 23, 2023 — ZAP Surgical Systems, Inc., a leading innovator in the field of surgical robotics, today announced that ...

Time May 23, 2023
arrow
News | Quality Assurance (QA)

March 16, 2023 — RTsafe, a leading provider of quality assurance products and services in stereotactic radiosurgery ...

Time March 16, 2023
arrow
News | Radiation Oncology

February 17, 2023 — Derry Crighton, a father of three from Scotland, says the Elekta Esprit radiosurgery system used to ...

Time February 17, 2023
arrow
News | Radiation Therapy

August 23, 2022 — Elekta announced that it has received CE mark for its Elekta Esprit, a new Leksell Gamma Knife ...

Time August 23, 2022
arrow
News | Radiation Therapy

March 15, 2022 — Above a certain size, individual brain metastases are often surgically removed with the help of ...

Time March 15, 2022
arrow
Sponsored Content | Videos | Radiation Therapy

Elekta’s latest linear accelerator, Harmony, is designed to provide a productive and versatile radiotherapy solution for ...

Time February 16, 2022
arrow
News | Radiation Oncology

January 27, 2022 — New guidelines for treating cancers that have spread to the brain are poised to improve care for ...

Time January 27, 2022
arrow
Videos | Radiation Therapy

The Elekta Harmony radiotherapy system gained FDA clearance in the summer of 2021 and was on display for the first time ...

Time November 17, 2021
arrow
Feature | ASTRO

November 8, 2021 — The following links to all the highlighted sessions presented at the American Society for Radiation ...

Time November 08, 2021
arrow
Subscribe Now